Latest news : CF PharmTech, Inc.

07-31	CF PharmTech Eyes HK$295 Million from Share Placement	MT
06-26	Cf Pharmtech, Inc. Announces Board and Supervisor Appointments, Effective June 26, 2026	CI
06-05	CF PharmTech Clears GMP Inspection for Suzhou Inhalation Drug Facility	MT
06-04	CF PharmTech, Inc. Inhalation Formulation Production Base Passes GMP Inspection in PIC/S Member Country	CI
06-01	CF Pharmtech, Inc. Receives IND Approval for ICF004 as a Class 1 New Drug by the NMPA	CI
05-31	CF PharmTech Wins China IND Approval for Lung Disease Drug Candidate	MT
05-31	CF PharmTech says NMPA approves IND application for ICF004 as class 1 new drug	RE
05-29	CF PharmTech, Inc. Announces Board and Supervisor Resignations, Effective May 29, 2026	CI
05-29	CF PharmTech Inc to nominate Zhang Jingjing as candidate for executive director	RE
05-28	Cf Pharmtech, Inc. Submitts Marketing Authorization Application for Cf017	CI
05-27	CF PharmTech Files Southeast Asia Marketing Authorization Application for Inhalation Drug; Shares Up 4%	MT
05-26	Cf Pharmtech, Inc. Marketing Authorization Application for Tiotropium Bromide Inhalation Powder Accepted by Nmpa	CI
05-25	CF PharmTech's Bronchospasm Secures China Marketing Approval	MT

More news

Managers and Directors: CF PharmTech, Inc.

Manager	Title	Age	Since
Wen Qing Liang CEO	Chief Executive Officer	60	2006-12-31
Li Li CTO	Chief Tech/Sci/R&D Officer	67	2020-08-31
Wei Wei DFI	Director of Finance/CFO	47	2021-11-14

Director	Title	Age	Since
Li Li BRD	Director/Board Member	67	2020-08-31
Wen Qing Liang CHM	Chairman	60	2006-12-31
Qi Li BRD	Director/Board Member	67	2020-08-31

More insiders

CF PharmTech, Inc. is a China-based company primarily the research and development, production and sale of respiratory drugs and other related medical products. The Companyâ€™s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.

Employees

540

Sector

Pharmaceuticals

Calendar

08-31 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-20	HK$15.91	+0.25%	1,800
26-08-20	HK$15.87	-3.23%	3,213,200
26-08-19	HK$16.40	-2.03%	2,958,200
26-08-18	HK$16.74	+0.06%	3,969,800
26-08-17	HK$16.73	-1.01%	4,993,900

Delayed Quote Hong Kong S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Hong Kong S.E. 21:30:57 2026-08-20 EDT			5-day change	1st Jan Change
15.91 ^HKD	+0.25%		-9.42%	-54.66%

Market Cap	5.59B 6.52B 831M 711M 664M 609M 1.14B 79.5B 1.17B 7.87B 3.07B 39.84B 3.12B 3.05B 132B	P/E 2024 *	-	P/E 2025	4,780x
Enterprise Value	5.08B 5.92B 755M 646M 603M 553M 1.04B 72.23B 1.06B 7.15B 2.79B 36.2B 2.83B 2.77B 120B	EV / Sales 2024 *	-	EV / Sales 2025	28.8x
Free-Float	55.71%	Yield 2024 *	-	Yield 2025	-

1 day	-3.23%
1 week	-9.42%
Current month	-20.13%
1 month	+2.06%
3 months	-21.44%
6 months	-55.92%
Current year	-54.66%

1 week	15.87	17.29
1 month	15.16	21.86
Current year	14.82	39.5
1 year	14.82	48.8
3 years	14.82	48.8
5 years	14.82	48.8
10 years	14.82	48.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/22/25	Wen Qing Liang	Other	Chief Executive Officer	6,500	0.0022%
12/22/25	Li Li	Other	Founder	6,500	0.0022%
12/19/25	Wen Qing Liang	Other	Chief Executive Officer	5,000	0.0017%

CF PharmTech, Inc. Stock

Stocks

2652

CNE1000074R9

Pharmaceuticals

Valuation: CF PharmTech, Inc.

Chart: CF PharmTech, Inc.

Latest news : CF PharmTech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CF PharmTech, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CF PHARMTECH, INC.	+0.25%	-9.42%	-	-	859M
ELI LILLY AND COMPANY	-2.81%	+2.93%	+76.40%	+127.73%	1,141B
JOHNSON & JOHNSON	-2.21%	+2.02%	+49.50%	+55.01%	659B
ABBVIE INC.	-1.56%	+4.39%	+25.19%	+74.39%	470B
ROCHE HOLDING AG	+1.20%	+2.62%	+41.69%	+45.78%	366B
NOVARTIS AG	-0.61%	+2.10%	+23.43%	+41.34%	302B
ASTRAZENECA PLC	+0.32%	+3.25%	+0.94%	+13.42%	254B
AMGEN INC.	-1.95%	+3.80%	+46.31%	+65.66%	239B
NOVO NORDISK A/S	-1.10%	-0.70%	-14.31%	-52.66%	207B
GILEAD SCIENCES, INC.	-2.82%	+3.84%	+20.81%	+89.04%	183B
Average	-1.48%	+2.77%	+30.00%	+51.08%	382.18B
Weighted average by Cap.	-1.64%	+3.12%	+43.48%	+70.86%

	2024	2025
Net sales	608M 709M 90.36M 77.37M 72.18M 66.23M 124M 8.65B 127M 856M 334M 4.33B 339M 332M 14.35B	433M 504M 64.31M 55.06M 51.37M 47.14M 88.57M 6.15B 90.32M 609M 238M 3.08B 241M 236M 10.21B
Net income	21.09M 24.59M 3.14M 2.68M 2.5M 2.3M 4.32M 300M 4.4M 29.71M 11.58M 150M 11.77M 11.52M 498M	2.48M 2.9M 369K 316K 295K 271K 509K 35.35M 519K 3.5M 1.36M 17.72M 1.39M 1.36M 58.65M
Net Debt	-275M -321M -40.89M -35.01M -32.66M -29.97M -56.32M -3.91B -57.43M -387M -151M -1.96B -154M -150M -6.49B	-511M -595M -75.92M -65.01M -60.65M -55.65M -105M -7.26B -107M -720M -280M -3.64B -285M -279M -12.05B